EMA Authorised: Lamivudine Teva Pharma B.V. (lamivudine) — Teva B.V.

View source ↗

Summary

The EMA has authorised Lamivudine Teva Pharma B.V. for HIV infections, with Teva B.V. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Lamivudine Teva Pharma B.V. (lamivudine)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Teva B.V.. Decision date: 21/04/2023